KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference53 articles.
1. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer;Brambilla;J Clin Oncol,2016
2. New strategies in lung cancer: translating immunotherapy into clinical practice;Forde;Clin Cancer Res,2014
3. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic;Chan;Ann Oncol,2019
4. Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers;Klein;Clin Cancer Res,2020
5. Current status of immune checkpoint inhibitor immunotherapy for lung cancer;Xiong;Front Oncol,2021
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Genetic profile of Chinese patients with small bowel cancer categorized by anatomic location;BMC Medical Genomics;2023-11-16
2. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC;Journal of Thoracic Oncology;2023-07
3. SPOCK2 and SPRED1 function downstream of EZH2 to impede the malignant progression of lung adenocarcinoma in vitro and in vivo;Human Cell;2023-01-11
4. High SERPINH1 expression predicts poor prognosis in lung adenocarcinoma;Journal of Thoracic Disease;2022-12
5. Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner;Cancers;2022-03-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3